Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...

Featured topics and Editors' Picks from all of ACC's JACC Journals. Vutrisiran and All-Cause Mortality, Prognostic Implication of sTTR Levels in ATTR-CM Studies exploring the association between ...

A U.S. court denied a motion from Toronto-based artificial intelligence company Cohere Inc. to dismiss a copyright lawsuit filed against it by major news organizations, including the Toronto Star.

Despite the many hours and lack of enthusiasm, the rating provides the transparency organizations need when making ...